Marine Organisms as Alkaloid Biosynthesizers of Potential Anti-Alzheimer Agents

Mar Drugs. 2022 Jan 15;20(1):75. doi: 10.3390/md20010075.

Abstract

The incidence of neurodegenerative diseases, such as Alzheimer's disease (AD), increases continuously demanding the urgent development of anti-Alzheimer's agents. Marine organisms (MO) have to create their own defenses due to the adverse environment where they live and so synthesize several classes of compounds, such as akaloids, to defend themselves. Therefore, the identification of marine natural products with neuroprotective effects is a necessity. Being that AD is not only a genetic but also an environmental complex disease, a treatment for AD remains to discover. As the major clinical indications (CI) of AD are extracellular plaques formed by β-amyloid (Aβ) protein, intracellular neurofibrillary tangles (NFTs) formed by hyper phosphorylated τ-protein, uncommon inflammatory response and neuron apoptosis and death caused by oxidative stress, alkaloids that may decrease CI, might be used against AD. Most of the alkalolids with those properties are derivatives of the amino acid tryptophan mainly with a planar indole scaffold. Certainly, alkaloids targeting more than one CI, multitarget-directed ligands (MTDL), have the potential to become a lead in AD treatment. Alkaloids to have a maximum of activity against CI, should be planar and contain halogens and amine quaternization.

Keywords: Alzheimer’s disease; MTDL; alkaloid; marine organism; sponge.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Animals
  • Aquatic Organisms*
  • Biological Products
  • Humans
  • Neuroprotective Agents / therapeutic use*

Substances

  • Biological Products
  • Neuroprotective Agents